Mutations in the gene encoding NLRP3 cause a spectrum of autoinflammatory diseases known as cryopyrin-associated periodic syndromes (CAPS) 1 . NLRP3 is a key component of one of several distinct cytoplasmic multiprotein complexes (inflammasomes) that mediate the maturation of the proinflammatory cytokine interleukin-1b (IL-1b) by activating caspase-1. Although several models for inflammasome activation, such as K 1 efflux 2 , generation of reactive oxygen species 3 and lysosomal destabilization 4 , have been proposed, the precise molecular mechanism of NLRP3 inflammasome activation, as well as the mechanism by which CAPS-associated mutations activate NLRP3, remain to be elucidated. Here we show that the murine calcium-sensing receptor (CASR) activates the NLRP3 inflammasome, mediated by increased intracellular Ca 21 and decreased cellular cyclic AMP (cAMP). Ca 21 or other CASR agonists activate the NLRP3 inflammasome in the absence of exogenous ATP, whereas knockdown of CASR reduces inflammasome activation in response to known NLRP3 activators. CASR activates the NLRP3 inflammasome through phospholipase C, which catalyses inositol-1,4,5-trisphosphate production and thereby induces release of Ca 21 from endoplasmic reticulum stores. The increased cytoplasmic Ca 21 promotes the assembly of inflammasome components, and intracellular Ca 21 is required for spontaneous inflammasome activity in cells from patients with CAPS. CASR stimulation also results in reduced intracellular cAMP, which independently activates the NLRP3 inflammasome. cAMP binds to NLRP3 directly to inhibit inflammasome assembly, and downregulation of cAMP relieves this inhibition. The binding affinity of cAMP for CAPS-associated mutant NLRP3 is substantially lower than for wild-type NLRP3, and the uncontrolled mature IL-1b production from CAPS patients' peripheral blood mononuclear cells is attenuated by increasing cAMP. Taken together, these findings indicate that Ca 21 and cAMP are two key molecular regulators of the NLRP3 inflammasome that have critical roles in the molecular pathogenesis of CAPS.
NLRP3 inflammasome activation by extracellular ATP is mediated through the purinergic receptor, P2X7R, and is inhibited by high concentrations of extracellular K 1 , which may block K 1 efflux
5
. However, ATP-driven NLRP3 inflammasome activation is also inhibited by other extracellular cations such as Ca 21 (ref. 6) . Hence, we initially explored the role of extracellular cations in inflammasome activation to investigate the signalling pathway that links danger-associated molecular patterns to the NLRP3 inflammasome. As seen in previous reports, addition of K 1 or Ca 21 with ATP to lipopolysaccharide (LPS)-primed mouse bone marrow-derived macrophages (BMDMs) suppressed bioactive IL-1b secretion, and the same effect was also observed with Mg 21 (Fig. 1a) . Surprisingly, we also found that in the absence of ATP, LPS-primed BMDMs secreted IL-1b when cultured with Ca 21 alone but not with Mg 21 or K 1 ( Fig. 1a and Supplementary Fig. 1a ). The Ca
21
-induced IL-1b secretion was independent of P2X7R, or the AIM2 (absent in melanoma 2) or NLRC4 (IPAF, ICE protease-activating factor) inflammasomes, but dependent on the NLRP3 inflammasome ( Fig. 1b and Supplementary Fig. 1b, c) . NLRP3 inflammasome activation was also induced by gadolinium (Gd 31 ), an agonist of CASR, or R-568, an allosteric agonist of CASR ( Supplementary Fig. 1d ). These results indicate that the recognition of extracellular Ca 21 through CASR activates the NLRP3 inflammasome. It seemed paradoxical that high calcium buffers could inhibit ATPinduced IL-1b secretion while stimulating IL-1b secretion in the absence of ATP. The inhibitory effect of extracellular Ca 21 was confined to NLRP3 co-stimulation with ATP, as high calcium buffers did not inhibit inflammasome activation by other NLRP3 activators, double-stranded DNA (dsDNA), or flagellin ( Supplementary Fig. 2a-c) . In addition, although both high calcium and high magnesium buffers inhibited ATP-induced inflammasome activation, equivalent concentrations of the trivalent cation Gd 31 (which, like Ca 21 itself, is an agonist of CASR) did not inhibit ATP-induced inflammasome activation ( Supplementary Fig. 2d ). One possible explanation for these observations is the well-recognized interaction between divalent cations and ATP, in which unbound ATP acts as the agonist form 7, 8 . Indeed, when BMDMs were treated with a given stimulatory concentration of Ca 21 , varying ATP concentrations, and vice versa, we observed first decreasing IL-1b production as inactive Ca 21 /ATP complexes form, and then eventually increasing IL-1b activation as the ATP or Ca 21 exceeded the available free Ca 21 or ATP, respectively (Supplementary Fig. 2e , f). Next, to examine the role of CASR in NLRP3 inflammasome activation further, the Casr gene was knocked down in mouse BMDMs by short interfering RNA (siRNA; Supplementary Fig. 3a , b). Similar to Nlrp3 or Asc knockdowns, IL-1b secretion from the BMDMs with Casr knockdown was substantially diminished in response to extracellular Ca 21 ( Fig. 1c) . Furthermore, we also observed that downregulation of Casr reduced IL-1b secretion when BMDMs were stimulated with several other known NLRP3 inflammasome activators, but not with AIM2 or NLRC4 inflammasome activators ( Fig. 1c and Supplementary Fig. 4 ). These findings suggest that CASR is an upstream gatekeeper of the NLRP3 inflammasome.
Intracellular Ca 21 signalling is important for NLRP3 inflammasome activation induced by extracellular ATP 9 . Elevation of extracellular Ca 21 concentrations or other CASR agonists commonly elicits intracellular Ca 21 signals through the interaction between CASR and phospholipase C (PLC) 10, 11 . We observed a correlation between PLC activity and the presence of active IL-1b in the supernatant of LPS-primed BMDMs. Cells treated with 2,4,6-trimethyl-N-[3-(trifluoromethyl)-phenyl]benzenesulphonamide (m-3M3FBS), a direct activator of PLC ( Fig. 2a) , secreted IL-1b in the absence of any other exogenous stimulus, indicating a role for PLC-stimulated Ca 21 signals in inflammasome activation. In contrast, PLC inhibitors edelfosine or U73122 (but not U73343, an inactive analogue of U73122) blocked IL-1b secretion from cells treated with Ca 21 or ATP (Supplementary Fig. 5a and Fig. 2b ). U73122 had no effect on AIM2 or NLRC4 inflammasome activation ( Supplementary Fig. 5b ), indicating that PLC activation is dispensable for triggering these inflammasomes.
PLC hydrolyses phosphatidylinositol-4,5-bisphosphate into diacyl glycerol (DAG), which activates protein kinase C, and inositol trisphosphate (InsP 3 ), which causes the cytosolic concentration of Ca 21 to increase by binding to InsP 3 receptors (InsP 3 R) in the endoplasmic reticulum (ER). Indeed, we observed generation of InsP 3 in BMDMs exposed to the NLRP3 inflammasome activators ATP or Ca 21 ( Fig. 2c) . When LPS-primed BMDMs were stimulated with ATP or Ca 21 in the presence of an InsP 3 R inhibitor (2-APB), little or no IL-1b was secreted (Fig. 2d) , whereas IL-1b secretion was not suppressed in the presence of protein kinase C inhibitors ( Supplementary Fig. 5c ). Moreover, in BMDMs in which the InsP3 receptor (Ip3r; also called Itpr1) had been knocked down, IL-1b secretion induced by extracellular Ca 21 or ATP was substantially reduced (Fig. 2e) . In addition, when wild-type cells were stimulated with ATP, CaCl 2 , or GdCl 3 , we observed increased intracellular Ca 21 levels, which were blocked by 2-APB or BAPTA-AM ( Supplementary Fig. 6a -c and Supplementary Videos 1-9), and IL-1b secretion, but not IL-6 or TNF-a secretion, was markedly inhibited by chelating intracellular Ca 21 with BAPTA-AM but not the heavy metal chelator TPEN ( Fig. 2f and Supplementary Fig. 7a, b) . Conversely, inflammasome activation was observed in LPS-primed BMDMs by treatment with thapsigargin, which increases intracellular Ca 21 ( Supplementary Fig. 7c ). BAPTA-AM or 2-APB did not block IL-1b secretion induced by dsDNA or flagellin (Fig. 2d, f) , which do not induce intracellular Ca 21 increases (data not shown). Taken together, these data indicate that activation of the AIM2 and NLRC4 inflammasomes is independent of InsP 3 R signalling and intracellular Ca 21 , whereas signalling from CASR activates the NLRP3 inflammasome via InsP 3 -mediated intracellular Ca 21 release. Indeed, the NLRP3-ASC association in cell-free lysates from BMDMs increased in the presence of Ca 21 ( Fig. 2g ), whereas Ca 21 had no direct effect on the activity of caspase 1 ( Supplementary Fig. 7d ). Nevertheless, it remains to be elucidated whether the role of Ca 21 on NLRP3 inflammasome activation is direct or indirect.
CASR interacts not only with PLC but also with adenylate cyclase (ADCY), which results in inhibition of ADCY and subsequent reduction 
RESEARCH LETTER
of cellular cAMP levels 10 . Indeed, addition of ATP or Ca 21 reduced the LPS-mediated cAMP increase in BMDMs 12 (Fig. 3a) . Thus, we also investigated a possible role for cAMP in inflammasome activation. Notably, an inverse correlation between the levels of cAMP and IL-1b secretion was observed in LPS-primed BMDMs. The increase of cAMP synthesis by ADCY activators (NKH477 or forskolin) or the decrease of cAMP hydrolysis by phosphodiesterase (PDE) 4 inhibitors (Ro-20-1724, (R)-(-)-rolipram, or zardaverine) suppressed IL-1b secretion, but not IL-6 or TNF-a secretion, and ASC oligomerization induced by ATP or Ca 21 , but did not inhibit cytokine secretion induced by dsDNA or flagellin (Fig. 3b, c and Supplementary Fig. 8a-e) . In contrast, an ADCY inhibitor (KH7) alone induced dose-dependent secretion of IL-1b and ASC oligomerization in wild-type BMDMs, but not in BMDMs from Nlrp3 2/2 , Asc 2/2 or Casp1 2/2 mice ( Supplementary  Fig. 8f and Fig. 3d) . Using knockdown experiments, we found that ADCY and PLC are downstream of CASR in NLRP3 activation, and that these pathways are intact even after Casr knockdown ( Supplementary Fig. 8g ). We also observed that the NLRP3-ASC interaction in KH7-treated BMDM lysates increased, whereas the interaction in lysates from forskolin-treated cells decreased (Fig. 3e) . Consistent with these data, spontaneous inflammasome activation was observed in BMDMs upon knockdown of the several adenylate cyclases (Fig. 3f ) that are expressed in macrophages (ADCY3, ADCY6, ADCY7 and ADCY9; Supplementary Fig. 8h ). Taken together, these results indicate that cAMP specifically suppresses NLRP3 inflammasome activation.
A major role of cAMP is activating protein kinase A (PKA), which could potentially suppress inflammasome activation. However, no IL1b secretion was observed in the supernatant of LPS-primed BMDMs treated with PKA inhibitors or after knockdown of Prkaca (also called Pkaa) ( Supplementary Fig. 9a, b) . To understand how cAMP might suppress NLRP3 inflammasome activation, we tested whether cAMP interacts directly with NLRP3. In a pull-down assay, we found an interaction of endogenous NLRP3 from BMDMs with cAMP but not with cGMP (Fig. 3g) . We also found that this interaction was mediated by the nucleotide-binding domain (NBD, also known as NACHT) of NLRP3 (Fig. 3h) , which has previously been shown to bind and hydrolyse ATP 13 . However, cAMP does not inhibit binding of ATP to NLRP3 (Supplementary Fig. 8i ).
Because cAMP suppresses NLRP3 inflammasome activation and binds to the NBD of NLRP3, which is the most common location of CAPS-associated mutations 1 , we considered the possible effect of these mutations on binding to cAMP. The binding of cAMP to the diseaseassociated mutant NLRP3 (D303N, A352V and F523C) was substantially decreased relative to wild-type NLRP3 (Fig. 4a) , which indicates that the spontaneous activation of the inflammasome in myeloid cells of patients with CAPS might be due to reduced suppression of NLRP3 activation by cAMP. Thus, we investigated the effect of cAMP on IL-1b secretion from peripheral blood mononuclear cells (PBMCs) of CAPS (familial cold autoinflammatory syndrome, FCAS; MuckleWells syndrome, MWS; neonatal-onset multisystem inflammatory disease, NOMID) patients. As previously reported 14 , without any inflammasome activator, mutation-positive CAPS patients' PBMCs secreted IL-1b in response to LPS priming alone, whereas healthy control PBMCs did not secrete IL-1b ( Supplementary Fig. 10a-c) . However, IL-1b secretion from CAPS PBMCs was substantially blocked by activating ADCY or inhibiting PDE4 (Fig. 4b, c and Supplementary Fig. 10b-d) . In contrast, we observed no inhibitory effect of ADCY activator or PDE4 inhibitors on IL-1b secretion from PBMCs of patients with familial Mediterranean fever (FMF) (Supplementary Fig. 10e ), the prototypic autoinflammatory disease which is caused by mutations of pyrin that induce an NLRP3-independent inflammasome 15 . These results are consistent with the hypothesis that the inhibitory effect of cAMP on IL-1b secretion is specific to the NLRP3 inflammasome.
In addition, we found that the constitutive IL-1b secretion from CAPS PBMCs was also substantially reduced by blockers of InsP 3 -mediated intracellular Ca 21 signalling pathways, 2-APB and BAPTA-AM, (Fig. 4d, e and Supplementary Fig. 10f, g ), which can also inhibit NLRP3 inflammasome activation induced by ATP or extracellular Ca 21 ( Fig. 2d, f) . These data indicate an essential role for intracellular Ca 21 signalling in CAPS-associated mutant NLRP3 activation. Using a combination of genetic, pharmacological and biochemical approaches, we provide evidence that CASR has a major role in NLRP3 inflammasome activation through its effects on intracellular Ca 21 and cAMP (summarized in Supplementary Fig. 11 and modelled in Supplementary Fig. 12 ), which also suggests a possible role for extracellular Ca 21 as a danger signal. Indeed, extracellular fluid at sites of injury and inflammation has been reported to contain high concentrations of Ca 21 , attracting cells of the monocyte/macrophage lineage 16 . The CASR is a G-protein-coupled receptor that interacts directly not only with Ga q eliciting intracellular Ca 21 signals through PLC, but 
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also with G i a, which results in the inhibition of ADCY and a reduction in cellular cAMP levels 10 . It has been widely recognized that in inflammatory cells, cAMP acts as a negative regulator of immune and inflammatory responses 17, 18 . Our results clarify a molecular mechanism for how cAMP inhibits IL-1b maturation in macrophages. As a second messenger, cAMP exerts its role by direct binding to the regulatory unit or domain of target proteins, thereby inducing conformational changes 19, 20 . The low binding affinity of cAMP with CAPSassociated mutant NLRP3 proteins and inhibition of IL-1b secretion from CAPS PBMCs by activation of ADCY or the inhibition of PDE4 is also consistent with an inhibitory effect of cAMP on NLRP3 inflammasome activation. Although IL-1 inhibition is currently being used as an effective therapy for CAPS, our data indicate a broader spectrum of potential targets for therapy of CAPS as well as other inflammatory conditions involving the NLRP3 inflammasome, including gout 21 , type 2 diabetes mellitus 3, 22 , atherosclerosis 23 and Alzheimer's disease 24 . 2000 ; flagellin, 0.5 mg ml 21 with 25 ml ml 21 DOTAP). For the inhibition of inflammasome activation, LPS-primed BMDMs were treated with inhibitors (U73122, 10 mM; U73343, 10 mM; edelfosine, 4-100 mM; 2-APB, 10 or 50 mM; BAPTA-AM, 10 or 20 mM; forskolin, 10-500 mM; NKH477, 10-500 mM; Ro 20-1724, 50-250 mM; (R)-(-)-rolipram, 50-250 mM; zardaverine, 100 or 250 mM; GF 109203X, 50 mM; C-1, 50 mM) in the presence of each activator. Immunoprecipitation and pull-down assay. The lysates from BMDMs or 293T cells transiently co-transfected with expression constructs for the wild type, CAPSassociated mutant, or various deleted forms of NLRP3 were immunoprecipitated with anti-ASC antibody followed by protein A agarose, or pulled down with preconjugated cAMP, cGMP or ATP beads. Biochemical assays. Mouse IL-1b, IL-6 and TNF-a in cell culture supernatants and InsP 3 and cAMP in cell lysates were measured using ELISA. RESEARCH LETTER
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